Arbutus Biopharma
ABUS
ABUS
130 hedge funds and large institutions have $298M invested in Arbutus Biopharma in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 49 increasing their positions, 30 reducing their positions, and 10 closing their positions.
Holders
130
Holders Change
+12
Holders Change %
+10.17%
% of All Funds
1.89%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.07%
New
23
Increased
49
Reduced
30
Closed
10
Calls
$11M
Puts
$1.28M
Net Calls
+$9.77M
Net Calls Change
-$1.43M
Top Buyers
| 1 |
1
Morgan Stanley
New York
|
$64.8M |
| 2 |
RCMNY
2
Rubric Capital Management (New York)
New York
|
$5.19M |
| 3 |
ACM
3
ADAR1 Capital Management
Austin,
Texas
|
$10.2M |
| 4 |
4
BlackRock
New York
|
$35.7M |
| 5 |
5
Vanguard Group
Malvern,
Pennsylvania
|
$21.7M |
